2,3-Dihydro-isoindol-1-one derivatives
AssigneeHoffman-La Roche Inc.
InventorsSynese Jolidon, Rosa Maria Rodriguez-Sarmiento, Andrew William Thomas, Rene Wyler
Life of this patent
Estimating the term…
Abstract
2,3-Dihydro-isoindol-1-one derivatives, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them, for the prevention and treatment of diseases which are mediated by monoamine oxidase B.
Claims60
A compound of formula I or II
- 10
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A compound of formula I
- 11
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A compound of formula I
- 12
- wherein
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7— (CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A compound of formula II
- 13
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n iso, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A compound of calim 26 wherein R2 is hydrogen or C1-C6-alkyl.
A compound of formula Ia
- 14
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A compound selected from
- 2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
- 2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
- (S)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
- (R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
- 2-[5-(4-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide, or
- 2-[1-oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetamide.
A compound which is 5-(3-fluoro-benzyloxy)-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one.
A compound selected from
- 2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
- (R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
- (S)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide, and
- (R)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide.
A compound selected from
- [6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester and
- [1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester.
A compound selected from
- 2-(2-methoxy-ethyl)-6-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one and
- 2-(2-methoxy-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one.
A compound selected from
- 2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride and
- 2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride.
A composition comprising a compound of formula I or II
- 15
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
A method of treating Alzheimer's disease by administering to an individual an effective amount of a compound of formula I or II
- 18
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A method of treating Parkinson's disease by administering to an individual an effective amount of a compound of formula I or II
- 19
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)n—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
A method of treating senile dementia by administering to an individual an effective amount of a compound of formula I or II
- 20
- wherein
- X is —N═ or —CH═;
- R1 is —(CH2)r—CO—NR5R6, —(CH2)n—NR5R6, —(CH2)n—COOR7, —(CH2)n—CN, —(CH2)n-isoindole-1,3-dionyl, or —(CH2)p—OR8;
- R2 is hydrogen, C1-C6-alkyl, or OH;
- R3 is hydrogen or C1-C6-alkyl;
- R4 is (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy;
- R5 and R6 are each independently hydrogen or C1-C6-alkyl;
- R7 is C1-C6-alkyl;
- R8 is hydrogen or C1-C6-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2;
- and
- p is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.